Interventional Oncology Market by Product (Radiofrequency, microwave, embolization, guidewires), Procedure (Thermal, Non-Thermal Ablation, TACE, TARE, TAE), Cancer (Liver, Lung, Kidney, Bone Metastasis), End User (Hospital, ASC) & Region - Global Forecast to 2026
Updated on : April 12, 2023
The global interventional oncology market in terms of revenue was estimated to be worth $1.9 billion in 2020 and is poised to reach $2.9 billion by 2026, growing at a CAGR of 6.8% from 2020 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The global market growth is driven by the ongoing technological advancements in cancer therapies & MIS surgeries, rising incidence of cancer & tumors, growing reimbursement coverage for cancer treatment in significant markets, and increased public-private investments for novel cancer therapies.
To know about the assumptions considered for the study, Request for Free Sample Report
Interventional Oncology Market Dynamics
Driver: Rising patient preference for minimally invasive procedures
In recent years, the demand for minimally invasive procedures has witnessed a significant increase owing to the advantages offered by these procedures over traditional treatment procedures. The key benefits of minimally invasive procedures include fewer operative complications, shorter hospitalization, less pain, smaller and more cosmetic incisions, lower risk of infection, reduced post-operative care, and quicker recovery. Minimally invasive procedures use advanced technologies to diagnose and treat various diseases, including cancer. These procedures are a practical approach to removing cancer tumors and lymph nodes without scarring. Minimally invasive techniques also assist surgeons in collecting tissues for biopsy and accurate staging studies. This, in turn, helps surgeons make an appropriate and exact cancer treatment plan.
Restraint: Dearth of well-trained and skilled radiologists and oncologists
The interventional oncology market is witnessing continuous technological innovations and advancements to make the devices and techniques more accurate and specific. However, interventional oncology is a technique wherein high standards can only be achieved and maintained by full-time specialists. As a result, the shortage of well-trained and skilled radiologists and oncologists is expected to affect the growth of the global market. For instance, more than 2,300 medical oncologists shortage is expected in the US by 2025 (Source: Journal of Global Oncology). The effect of this factor will be more pronounced in developing and underdeveloped regions. One of the significant obstacles in delivering care for patients with curable cancers in the sub-Saharan African region is the shortage of medical oncologists, radiation oncologists, and other healthcare workers required for cancer care. Similarly, India is facing an acute shortage of oncologists, radiotherapists, and surgical oncologists. This shortage of oncologists and radiologists in several countries across the globe is expected to affect the adoption of interventional oncology procedures in their respective healthcare systems despite the presence of a large target patient population.
Opportunity: Emerging economies offer high growth potential
Rapid economic development and increasing healthcare expenditure in several emerging countries such as China, India, Brazil, and Mexico are expected to improve access to quality healthcare. This is considered a positive indicator of the growth of the interventional oncology market.
The rising incidence of cancer in these countries results in a growth in the demand for various interventional oncology products and procedures. According to GLOBOCAN 2018, there were 609,596 new liver cancer cases in the Asian region in 2018, and this figure is projected to increase by 142,982 by 2025. As a result of the growing disease burden, governments in several emerging countries invest heavily in developing and modernization of their healthcare infrastructures.
Challenge: Limited clinical data to support therapeutic efficacy
For a treatment to be implemented as a standard of care, rigorous safety data from Phase I trials, demonstrated efficacy from Phase II trials, and evaluation of clinical outcomes better than available treatments from randomized, controlled Phase III trials are required. However, conducting well-controlled clinical trials in interventional oncology procedures is difficult due to the lack of established methodologies. For instance, chemoembolization is the most commonly used procedure for hepatocellular carcinoma. However, the clinical evidence supporting chemoembolization is weak, and the clinical benefits derived from the current trials are lower than the other available treatment options for cancer.
Thus, the limited clinical evidence supporting the benefits of interventional oncology and incorporating strategies to improve the therapeutic outcomes and safety of interventional oncology practices are considered critical challenges for the growth of this market during the forecast period.
Embolization devices to witness the highest revenue share in the interventional oncology market during the forecast period.
Embolization devices account for the largest share of the global market as of 2022. Embolization devices include non-radioactive embolic agents and radioembolic agents. Although these devices are primarily employed to treat hepatocellular carcinoma, their use has been widely extended to various other forms of cancer. These devices are used when tumors cannot be treated using ablation techniques and in cases where the tumor size is large. They are also used in palliative procedures and as a pre-operative procedure to improve the outcome of liver resection.
Liver cancer accounts for the largest interventional oncology market in 2022.
Liver cancer accounts for the largest interventional oncology market in 2022. The large share of this segment can be attributed to factors such as rising cases of liver cancer across the globe and growing initiatives/research activities to develop advanced liver cancer therapies using interventional oncology. In addition, initiatives in the form of grants and funding for developing advanced treatments using interventional oncology also fuel market growth.
Hospitals & diagnostic centers to account for the largest share of the interventional oncology market in 2022
Hospitals & diagnostic centers to account for the largest share of the global market in 2022. This is owing to the greater availability of state-of-the-art facilities for treating cancers, the growing number of minimally invasive surgeries performed in hospitals, and the adoption of robotic surgery.
The Asia Pacific region of the interventional oncology market will grow at the highest CAGR during the forecast period.
The market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Government efforts to increase funding, supportive regulations for the development and commercialization of advanced interventional oncology products, rising healthcare expenditure, an increasing number of hospitals and clinics in India and China, expanding research base across India, China, and Japan, and the increasing incidence of surgeries are the major factors driving the growth of the APAC market.
Medtronic (Ireland), Boston Scientific (US), BD (US), Terumo (Japan), Merit Medical (US), AngioDynamics (US), J&J (US), Teleflex (US), Cook Medical (US), HealthTronics (US), MedWaves (US), Sanarus (US), IMBiotechnologies (Canada), Trod Medical (US), IceCure Medical (Israel), Mermaid Medicals (Denmark), Interface Biomaterials BV (Netherlands), Guerbet (France), ABK Biomedical (Canada), Shape Memory Medical (US), Endo Shape (US), Monteris Medical (US), Instylla (US), Trisalus Lifesciences (US), Profound Medical Corp (Canada), Sirtex (US), Accuray (US), Baylis Medical (Canada), and ALPINION MEDICAL SYSTEMS (South Korea).
Boston Scientific (US) dominated the global interventional oncology market in 2020. The company mainly focuses on growth strategies such as acquisitions and expansions to increase its market presence and product offerings. The company’s plan to acquire BTG will help expand its product offerings in chemoembolization, radioembolization, and ablation therapies. Boston Scientific constantly strives to gain regulatory and reimbursement approvals. As a part of its long-term growth strategy, the company invests in fast-growing markets as well as new markets by strengthening its position in the global healthcare market.
Interventional Oncology Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2020 |
$1.9 billion |
|
Projected Revenue by 2026 |
$2.9 billion |
|
Revenue Growth Rate |
Poised to grow at a CAGR of 6.8% |
|
Market Segmentation |
Product, Procedure, Cancer Type, End User & Region |
|
Market Driver |
Rising patient preference for minimally invasive procedures |
|
Market Opportunity |
Emerging economies offer high growth potential |
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
This research report categorizes the interventional oncology market to forecast revenue and analyze trends in each of the following submarkets:
By Product
-
Embolization Devices
- Radioembolic Agents
-
Non-Radio embolic Agents
- Microspheres
- Coated Beads
- Microparticles
-
Ablation Devices
- Radiofrequency (RF) Ablation Devices
- Microwave Ablation Devices
- Cryoablation Devices
- Other Ablation Devices
-
Support Devices
- Microcatheters
- Guidewires
By Procedure
- Thermal Tumor Ablation
- Non-Thermal Tumor Ablation
- Transcatheter Arterial Chemoembolization
- Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
- Transcatheter Arterial Embolization/Bland Embolization
By Cancer Type
- Liver Cancer
- Lung Cancer
- Bone Metastasis
- Kidney Cancer
- Breast Cancer
- Prostate Cancer
- Other Cancers
By End Users
- Hospitals
- Ambulatory Surgery Centers
- Research & Academic Institutes
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- RoE
-
Asia Pacific
- Japan
- China
- India
- RoAPAC
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
Recent Developments
- In 2021, Boston Scientific (US) launched Launched the TheraSphere Y-90 Glass Microspheres
- In 2018, Merit Medical Systems (US) launched the Preclude IDeal Hydrophilic Sheath Introducer in EMEA markets
- In 2018, IMBiotechnologies (US) launched ‘Ekobi 500 Embolization Microspheres’ with an enhanced feature of detectability using ultrasound technology.
- In 2018, Medical City and distributor Gulf Medical Company to install the first IMRIS Surgical Theatre in Saudi Arabia.
- In 2018, Medtronic (Ireland) launched its OptiSphere embolization spheres designed for hypervascular tumor embolization in the US
Frequently Asked Questions (FAQs):
What is the projected market value of the global interventional oncology market?
The global interventional oncology market boasts a total revenue value of $1.9 billion in 2020 and is projected to register a revenue value of $2.9 billion by 2026.
What is the estimated growth rate (CAGR) of the global interventional oncology market for the next five years?
The global interventional oncology market in terms of revenue is poised to grow at a CAGR of 6.8%.
What does the current study of the interventional oncology market consist of?
The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 30)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 35)
2.1 RESEARCH DATA
FIGURE 1 INTERVENTIONAL ONCOLOGY MARKET: RESEARCH METHODOLOGY STEPS
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 BREAKDOWN OF PRIMARIES: GLOBAL MARKET
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2 MARKET SIZE ESTIMATION
2.2.1 PRODUCT-BASED MARKET ESTIMATION
FIGURE 5 GLOBAL MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 6 GLOBAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
2.2.2 PRIMARY RESEARCH VALIDATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 7 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 45)
FIGURE 8 INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2020 VS. 2026 (USD MILLION)
FIGURE 9 GLOBAL MARKET SHARE, BY PROCEDURE, 2020
FIGURE 10 GLOBAL MARKET, BY CANCER TYPE, 2020 VS. 2026 (USD MILLION)
FIGURE 11 GLOBAL MARKET, BY END USER, 2020 VS. 2026 (USD MILLION)
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 49)
4.1 INTERVENTIONAL ONCOLOGY MARKET OVERVIEW
FIGURE 13 RISING PREFERENCE FOR MINIMALLY INVASIVE PROCEDURES IS DRIVING THE GROWTH OF THE GLOBAL MARKET
4.2 GLOBAL MARKET, BY PRODUCT
FIGURE 14 EMBOLIZATION DEVICES TO ACCOUNT FOR THE LARGEST SHARE OF THE MARKET DURING THE FORECAST PERIOD
4.3 ASIA PACIFIC: MARKET, BY PRODUCT (2020)
FIGURE 15 EMBOLIZATION DEVICES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2020
4.4 EUROPE: MARKET, BY CANCER TYPE (2020)
FIGURE 16 LIVER CANCER COMMANDED THE LARGEST SHARE OF THE EUROPEAN MARKET IN 2020
4.5 GLOBAL MARKET, BY END USER, 2020 VS. 2026 (USD MILLION)
FIGURE 17 HOSPITALS TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
4.6 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL MARKET
FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR IN THE GLOBAL MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 54)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 INTERVENTIONAL ONCOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising patient preference for minimally invasive procedures
5.2.1.2 Expansion of the target patient population
5.2.1.3 Increasing public-private funding and government support for interventional oncology
5.2.1.4 Technological advancements in interventional oncology
5.2.2 RESTRAINTS
5.2.2.1 Dearth of well-trained and skilled radiologists and oncologists
5.2.2.2 Unfavorable regulations
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging economies offer high growth potential
5.2.3.2 Rising awareness about the benefits of interventional oncology
5.2.4 CHALLENGES
5.2.4.1 Limited clinical data to support therapeutic efficacy
5.2.4.2 Strong market positioning of alternative therapies
5.3 MARKET TRENDS
5.3.1 PERSONALIZED OR PRECISION INTERVENTIONAL ONCOLOGY
5.4 REGULATORY SCENARIO
5.4.1 US
5.4.1.1 Japan
TABLE 1 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
5.5 ECOSYSTEM COVERAGE
5.6 VALUE CHAIN ANALYSIS
5.7 PRICING ANALYSIS
6 INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT (Page No. - 64)
6.1 INTRODUCTION
TABLE 2 GLOBAL MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
6.2 EMBOLIZATION DEVICES
TABLE 3 RECENT PRODUCT LAUNCHES AND APPROVALS OF EMBOLIZATION DEVICES
TABLE 4 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 5 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.1 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET SPLIT, BY PROCEDURE
TABLE 6 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
6.2.2 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET SPLIT, BY CANCER TYPE
TABLE 7 INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
6.2.3 RADIOEMBOLIC AGENTS
6.2.3.1 Radioembolic agents dominated the interventional oncology embolization devices market
TABLE 8 RADIOEMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
TABLE 9 RADIOEMBOLIC AGENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.3.1.1 Radioembolic agents market split, by procedure
TABLE 10 RADIOEMBOLIC AGENTS MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
6.2.3.1.2 Radioembolic agents market split, by cancer type
TABLE 11 RADIOEMBOLIC AGENTS MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
6.2.4 NON-RADIOACTIVE EMBOLIC AGENTS
6.2.4.1 Embolization procedures cannot be used to treat cancers in advanced stages, which is a major factor restraining market growth
TABLE 12 NON-RADIOACTIVE EMBOLIC AGENTS OFFERED BY MAJOR MARKET PLAYERS
TABLE 13 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 14 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.2.4.1.1 Non-radioactive embolic agents market split, by procedure
TABLE 15 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
6.2.4.1.2 Non-radioactive embolic agents market split, by cancer type
TABLE 16 NON-RADIOACTIVE EMBOLIC AGENTS MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
6.2.4.2 Microspheres
6.2.4.2.1 Preference for alternative procedures limits the growth of this market segment
TABLE 17 GLOBAL MARKET FOR MICROSPHERES, BY REGION, 2019–2026 (USD MILLION)
6.2.4.3 Coated beads
6.2.4.3.1 Coated beads are better at finding CTC cancer, driving the growth of this market segment
TABLE 18 GLOBAL MARKET FOR COATED BEADS, BY REGION, 2019–2026 (USD MILLION)
6.2.4.4 Microparticles
6.2.4.4.1 Microparticles can be used in various cancer applications—a key factor driving growth
TABLE 19 MAJOR BRANDS OF MICROCARRIERS
TABLE 20 GLOBAL MARKET FOR MICROPARTICLES, BY REGION, 2019–2026 (USD MILLION)
6.3 ABLATION DEVICES
TABLE 21 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 22 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.1 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET SPLIT, BY PROCEDURE
TABLE 23 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
6.3.2 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET SPLIT, BY CANCER TYPE
TABLE 24 INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
6.3.3 RADIOFREQUENCY (RF) ABLATION DEVICES
6.3.3.1 Growing competition among different technologies offered by key players, backed by long-term clinical efficacy data, to drive the RF ablation devices market 80
TABLE 25 RADIOFREQUENCY ABLATION DEVICES OFFERED BY MAJOR MARKET PLAYERS
TABLE 26 RADIOFREQUENCY ABLATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.3.1.1 Radiofrequency ablation devices market split, by procedure
TABLE 27 RADIOFREQUENCY ABLATION DEVICES MARKET, BY PROCEDURE,2019–2026 (USD MILLION)
6.3.3.1.2 Radiofrequency ablation devices market split, by cancer type
TABLE 28 RADIOFREQUENCY ABLATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
6.3.4 MICROWAVE ABLATION DEVICES
6.3.4.1 Microwave ablation enables the simultaneous treatment of multiple lesions—a key factor driving market growth
TABLE 29 MICROWAVE ABLATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.4.1.1 Microwave ablation devices market split, by procedure
TABLE 30 MICROWAVE ABLATION DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
6.3.4.1.2 Microwave ablation devices market split, by cancer type
TABLE 31 MICROWAVE ABLATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
6.3.5 CRYOABLATION DEVICES
6.3.5.1 Advantages of cryoablation over other thermal ablation techniques to drive market growth in the coming years
TABLE 32 CRYOABLATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.5.1.1 Cryoablation devices market split, by procedure
TABLE 33 CRYOABLATION DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
6.3.5.1.2 Cryoablation devices market split, by cancer type
TABLE 34 CRYOABLATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
6.3.6 OTHER ABLATION DEVICES
TABLE 35 OTHER ABLATION DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
6.3.6.1 Other ablation devices market split, by procedure
TABLE 36 OTHER ABLATION DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
6.3.6.2 Other ablation devices market split, by cancer type
TABLE 37 OTHER ABLATION DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
6.4 SUPPORT DEVICES
TABLE 38 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 39 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
6.4.1 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET SPLIT, BY PROCEDURE
TABLE 40 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
6.4.2 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET SPLIT, BY CANCER TYPE
TABLE 41 INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
6.4.3 MICROCATHETERS
6.4.3.1 Regulatory approvals driving the growth of the microcatheters market
TABLE 42 MICROCATHETERS MARKET, BY REGION, 2019–2026 (USD MILLION)
6.4.4 GUIDEWIRES
6.4.4.1 Advancements in guidewire construction and the launch of new and advanced products are the major factors driving the growth of this market
TABLE 43 GUIDEWIRES MARKET, BY REGION, 2019–2026 (USD MILLION)
7 INTERVENTIONAL ONCOLOGY MARKET, BY CANCER TYPE (Page No. - 91)
7.1 INTRODUCTION
TABLE 44 GLOBAL MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
7.1.1 LIVER CANCER
7.1.1.1 Increasing disease prevalence and rising research activities are driving market growth
TABLE 45 GLOBAL MARKET FOR LIVER CANCER, BY REGION, 2019–2026 (USD MILLION)
7.1.2 KIDNEY CANCER
7.1.2.1 For patients with small lesions, cryoablation is considered a first-line therapy as it preserves more kidney tissue than surgery
TABLE 46 GLOBAL MARKET FOR KIDNEY CANCER, BY REGION, 2019–2026 (USD MILLION)
7.1.3 BREAST CANCER
7.1.3.1 Growing number of breast cancer cases across the globe is fueling the adoption of IORT
TABLE 47 GLOBAL MARKET FOR BREAST CANCER, BY REGION, 2019–2026 (USD MILLION)
7.1.4 LUNG CANCER
7.1.4.1 Increasing number of cancer cases will drive the demand for interventional oncology procedures
TABLE 48 GLOBAL MARKET FOR LUNG CANCER, BY REGION, 2019–2026 (USD MILLION)
7.1.5 BONE CANCER
7.1.5.1 Interventional oncology procedures can eliminate tumors directly and relieve pain
TABLE 49 GLOBAL MARKET FOR BONE CANCER, BY REGION, 2019–2026 (USD MILLION)
7.1.6 PROSTATE CANCER
7.1.6.1 Technological advancements in radiology devices to fuel the adoption of interventional oncology for prostate cancer treatment
TABLE 50 GLOBAL MARKET FOR PROSTATE CANCER, BY REGION, 2019–2026 (USD MILLION)
7.1.7 OTHER CANCERS
TABLE 51 GLOBAL MARKET FOR OTHER CANCERS, BY REGION, 2019–2026 (USD MILLION)
8 INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE (Page No. - 99)
8.1 INTRODUCTION
TABLE 52 GLOBAL MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
8.2 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY (TARE/SIRT)
8.2.1 TARE SHOWS GREATER CLINICAL EFFICACY THAN TACE—A KEY FACTOR DRIVING MARKET GROWTH
TABLE 53 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION/SELECTIVE INTERNAL RADIATION THERAPY PROCEDURES MARKET, BY REGION, 2019–2026 (USD MILLION)
8.3 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE)
8.3.1 ABILITY TO TREAT SMALL AND LARGE-SIZED TUMORS—A MAJOR FACTOR DRIVING THE DEMAND FOR TACE PROCEDURES
TABLE 54 TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION PROCEDURES MARKET, BY REGION, 2019–2026 (USD MILLION)
8.4 THERMAL TUMOR ABLATION
8.4.1 GROWING CLINICAL EVIDENCE PROVING THE EFFICACY OF THERMAL TUMOR ABLATION IN THE TREATMENT OF VARIOUS TYPES OF CANCERS TO DRIVE MARKET GROWTH
TABLE 55 THERMAL TUMOR ABLATION PROCEDURES MARKET, BY REGION, 2019–2026 (USD MILLION)
8.5 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION (TAE)
8.5.1 INCREASING CLINICAL EVIDENCE FOR TARE AND TACE TO RESTRAIN THE GROWTH OF THIS MARKET
TABLE 56 TRANSCATHETER ARTERIAL EMBOLIZATION/BLAND EMBOLIZATION PROCEDURES MARKET, BY REGION, 2019–2026 (USD MILLION)
8.6 NON-THERMAL TUMOR ABLATION
8.6.1 NANOKNIFE HAS EMERGED AS A POTENTIAL ALTERNATIVE TO THERMAL TUMOR ABLATION TECHNIQUES
TABLE 57 NON-THERMAL TUMOR ABLATION PROCEDURES MARKET, BY REGION, 2019–2026 (USD MILLION)
9 INTERVENTIONAL ONCOLOGY MARKET, BY END USER (Page No. - 107)
9.1 INTRODUCTION
TABLE 58 GLOBAL MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 HOSPITALS
9.2.1 HIGH PURCHASING POWER AND INCREASING NUMBER OF SURGERIES IN HOSPITALS TO SUPPORT THE GROWTH OF THIS SEGMENT
TABLE 59 GLOBAL MARKET FOR HOSPITALS, BY REGION, 2019–2026 (USD MILLION)
9.3 AMBULATORY SURGERY CENTERS
9.3.1 INCREASING NUMBER OF AMBULATORY SURGERY CENTERS TO DRIVE MARKET GROWTH
TABLE 60 GLOBAL MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2019–2026 (USD MILLION)
9.4 RESEARCH & ACADEMIC INSTITUTES
9.4.1 BUDGETARY RESTRICTIONS IN RESEARCH & ACADEMIC INSTITUTES ARE LIMITING THE ADOPTION OF HIGH-END INTERVENTIONAL ONCOLOGY PRODUCTS
TABLE 61 GLOBAL MARKET FOR RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
10 INTERVENTIONAL ONCOLOGY MARKET, BY REGION (Page No. - 112)
10.1 INTRODUCTION
TABLE 62 GLOBAL MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 20 NORTH AMERICA: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
TABLE 63 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 64 NORTH AMERICA: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 67 NORTH AMERICA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 NORTH AMERICA: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 69 NORTH AMERICA: MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
10.2.1 US
10.2.1.1 US to dominate the North American interventional oncology market
TABLE 70 US: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 71 US: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 72 US: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 73 US: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Public-private initiatives to support the adoption of interventional oncology procedures in Canada
TABLE 74 CANADA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,2019–2026 (USD MILLION)
TABLE 75 CANADA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 76 CANADA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 77 CANADA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 78 EUROPE: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 79 EUROPE: MARKET, BY PRODUCT,2019–2026 (USD MILLION)
TABLE 80 EUROPE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 81 EUROPE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 82 EUROPE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 83 EUROPE: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 84 EUROPE: MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Germany is the fastest-growing market in Europe
TABLE 85 GERMANY: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 86 GERMANY: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 GERMANY: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 88 GERMANY: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3.2 UK
10.3.2.1 Increasing awareness and support for cancer-related activities to drive market growth in the UK
TABLE 89 UK: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 90 UK: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 91 UK: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 92 UK: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Radiofrequency ablation dominated the ablation devices market in France
TABLE 93 FRANCE: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 94 FRANCE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 95 FRANCE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 96 FRANCE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Growing awareness about cancer and treatment options to support market growth in Italy
TABLE 97 ITALY: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 98 ITALY: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 99 ITALY: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 100 ITALY: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Growing geriatric population is a major factor driving market growth
TABLE 101 SPAIN: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 102 SPAIN: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 103 SPAIN: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 104 SPAIN: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 105 ROE: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT,2019–2026 (USD MILLION)
TABLE 106 ROE: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 107 ROE: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 108 ROE: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 21 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY MARKET SNAPSHOT
TABLE 109 ASIA PACIFIC: MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 110 ASIA PACIFIC: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 111 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 112 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 113 ASIA PACIFIC: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 114 ASIA PACIFIC: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 115 ASIA PACIFIC: MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Rising geriatric population and universal healthcare reimbursement are the major driving factors
TABLE 116 JAPAN: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 117 JAPAN: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 118 JAPAN: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 119 JAPAN: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Increasing cancer incidence and growing patient population to drive market growth in China
TABLE 120 CHINA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 121 CHINA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 122 CHINA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 123 CHINA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Improving research capabilities coupled with the expansion of key players to drive market growth in India
TABLE 124 INDIA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 125 INDIA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 126 INDIA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 127 INDIA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 Rising research investments and awareness campaigns are the key factors supporting market growth
TABLE 128 AUSTRALIA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 129 AUSTRALIA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 130 AUSTRALIA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 131 AUSTRALIA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET,BY TYPE, 2019–2026 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Rising R&D and promising clinical trials in the country to positively impact market growth
TABLE 132 SOUTH KOREA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 133 SOUTH KOREA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 134 SOUTH KOREA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 135 SOUTH KOREA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.4.6 REST OF ASIA PACIFIC
TABLE 136 ROAPAC: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 137 ROAPAC: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 138 ROAPAC: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 139 ROAPAC: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
TABLE 140 LATAM: INTERVENTIONAL ONCOLOGY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 141 LATAM: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 142 LATAM: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 143 LATAM: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 144 LATAM: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 145 LATAM: MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
TABLE 146 LATAM: MARKET, BY CANCER TYPE, 2019–2026 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Brazil to account for the largest share of the Latin American interventional oncology market
TABLE 147 BRAZIL: MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 148 BRAZIL: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 149 BRAZIL: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 150 BRAZIL: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Growing awareness campaigns and rising incidence of cancer to drive market growth in Mexico
TABLE 151 MEXICO: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 152 MEXICO: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 153 MEXICO: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 154 MEXICO: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.5.3 REST OF LATIN AMERICA
TABLE 155 ROLA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 156 ROLA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 157 ROLA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 158 ROLA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND RISING INCIDENCE OF CANCER ARE DRIVING GROWTH IN THE MIDDLE EAST & AFRICA
TABLE 159 MEA: INTERVENTIONAL ONCOLOGY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
TABLE 160 MEA: INTERVENTIONAL ONCOLOGY ABLATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 161 MEA: INTERVENTIONAL ONCOLOGY EMBOLIZATION DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 162 MEA: INTERVENTIONAL ONCOLOGY SUPPORT DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 163 MEA: INTERVENTIONAL ONCOLOGY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 158)
11.1 OVERVIEW
FIGURE 22 KEY DEVELOPMENTS IN THE GLOBAL MARKET FROM 2017 TO 2019
11.2 GLOBAL MARKET SHARE ANALYSIS, 2020
TABLE 164 MEDICAL TAPES AND BANDAGES MARKET: DEGREE OF COMPETITION
FIGURE 23 BOSTON SCIENTIFIC HELD THE LEADING POSITION IN THE INTERVENTIONAL ONCOLOGY MARKET IN 2020
11.3 COMPETITIVE LEADERSHIP MAPPING
11.4 VENDOR INCLUSION CRITERIA
11.5 VENDOR DIVE
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 24 GLOBAL MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2020
11.6 COMPETITIVE LEADERSHIP MAPPING: EMERGING COMPANIES/SMES/START-UPS (2020)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 25 GLOBAL MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2020 (SME/START-UPS)
11.7 COMPANY PRODUCT FOOTPRINT ANALYSIS
TABLE 165 PRODUCT FOOTPRINT OF COMPANIES
TABLE 166 INDUSTRY FOOTPRINT OF COMPANIES
TABLE 167 APPLICATION FOOTPRINT OF COMPANIES
TABLE 168 REGIONAL FOOTPRINT OF COMPANIES
11.8 COMPETITIVE SCENARIO (2017–2020)
11.8.1 KEY PRODUCT LAUNCHES
11.8.2 DEALS
12 COMPANY PROFILES (Page No. - 171)
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
12.1.1 BOSTON SCIENTIFIC CORPORATION
TABLE 169 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
FIGURE 26 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2019)
12.1.2 MEDTRONIC PLC
TABLE 170 MEDTRONIC PLC: BUSINESS OVERVIEW
FIGURE 27 MEDTRONIC PLC: COMPANY SNAPSHOT (2019)
12.1.3 JOHNSON & JOHNSON
TABLE 171 JOHNSON & JOHNSON: BUSINESS OVERVIEW
FIGURE 28 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2019)
12.1.4 TERUMO CORPORATION
TABLE 172 TERUMO CORPORATION: BUSINESS OVERVIEW
FIGURE 29 TERUMO CORPORATION: COMPANY SNAPSHOT (2020)
12.1.5 MERIT MEDICAL SYSTEMS, INC.
TABLE 173 MERIT MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW
FIGURE 30 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2019)
12.1.6 TELEFLEX, INC.
TABLE 174 TELEFLEX, INC.: BUSINESS OVERVIEW
FIGURE 31 TELEFLEX, INC.: COMPANY SNAPSHOT (2020)
12.1.7 ANGIODYNAMICS, INC.
TABLE 175 ANGIODYNAMICS, INC.: BUSINESS OVERVIEW
FIGURE 32 ANGIODYNAMICS: COMPANY SNAPSHOT (2020)
12.1.8 BECTON, DICKINSON AND COMPANY
TABLE 176 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
12.1.9 HEALTHTRONICS, INC.
TABLE 177 HEALTHTRONICS, INC.: BUSINESS OVERVIEW
12.1.10 TROD MEDICAL
TABLE 178 TROD MEDICAL: BUSINESS OVERVIEW
12.1.11 SANARUS TECHNOLOGIES, INC.
TABLE 179 SANARUS TECHNOLOGIES, INC.: BUSINESS OVERVIEW
12.1.12 IMBIOTECHNOLOGIES LTD.
TABLE 180 IMBIOTECHNOLOGIES LTD.: BUSINESS OVERVIEW
12.1.13 MEDWAVES, INC.
TABLE 181 MEDWAVES, INC.: BUSINESS OVERVIEW
12.1.14 ICECURE MEDICAL
TABLE 182 ICECURE MEDICAL: BUSINESS OVERVIEW
12.1.15 COOK MEDICAL
TABLE 183 COOK MEDICAL: BUSINESS OVERVIEW
12.2 OTHER COMPANIES
12.2.1 PROFOUND MEDICAL CORP.
12.2.2 SIRTEX MEDICAL
12.2.3 BAYLIS MEDICAL COMPANY, INC.
12.2.4 ACCURAY
12.2.5 ALPINION MEDICAL SYSTEMS
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 205)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
The study involved four major activities to estimate the current size of the interventional oncology market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources, such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to in order to identify and collect information for the interventional oncology market study.
Primary Research
The interventional oncology market comprises several stakeholders such as Interventional oncology product manufacturing companies, Product distributors and channel partners, Hospitals and surgical centers, Minimally invasive medical devices, ablation, and embolization product manufacturing companies, Commercial service providers, Clinical research organizations (CROs), Ablation and embolization service providers, Medical research laboratories, Academic medical centers and universities, Cancer research organizations, Government and non-governmental regulatory authorities, Market research and consulting firms. The demand side of this market is characterized by the increasing incidence of technological advancements and increased funding and public-private investments. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is the breakdown of primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the interventional oncology market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and markets have been identified through extensive secondary research
- The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size-using the market size estimation processes as explained above-the interventional oncology market was split into several segments and subsegments. In order to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the interventional oncology industry.
Report Objectives
- To define, describe, and forecast the interventional oncology market by product, procedure, cancer type, end user, and region
- To provide detailed information about the major factors influencing the market growth (such as key drivers, restraints, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and their contributions to the overall interventional oncology market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
-
To forecast the revenue of market segments with respect to five major regions, namely,
North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa - To profile the key players active in the interventional oncology market and comprehensively analyze their global revenue shares and core competencies2
- To track and analyze competitive market-specific developments such as product launches, collaborations, agreements, partnerships, expansions, and mergers & acquisitions in the interventional oncology market
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the interventional oncology market report:
Product Analysis
- Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players
Product Analysis
- Further breakdown of the Rest of European market into Poland, Nederland and other European countries (aggregated)
Company Information
- Detailed analysis and profiling of additional market players (up to 5 OEMs)
Generating Response ...
Growth opportunities and latent adjacency in Interventional Oncology Market